PDF herunterladen
Thromb Haemost 2018; 118(10): 1713-1728
DOI: 10.1055/s-0038-1669785
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

The First Intrinsic Tenase Complex Inhibitor with Serine Protease Structure Offers a New Perspective in Anticoagulant Therapy

Zorica Latinović
1   Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia
2   Jožef Stefan International Postgraduate School, Ljubljana, Slovenia
,
Adrijana Leonardi
1   Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia
,
Lidija Kovačič
1   Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia
3   Global Drug Development, Novartis Ireland Ltd, Dublin, Ireland
,
Cho Yeow Koh
4   Protein Science Laboratory, Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore
5   Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
,
Jernej Šribar
1   Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia
,
Alenka Trampuš Bakija
6   Division of Pediatrics, University Medical Center Ljubljana, University of Ljubljana, Ljubljana, Slovenia
,
Divi Venkateswarlu
7   Department of Chemistry, North Carolina Agricultural and Technical State University, Greensboro, North Carolina, United States
,
R. Manjunatha Kini
4   Protein Science Laboratory, Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore
,
Igor Križaj
1   Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia
› Institutsangaben Funding This work was supported by a grant from the Slovenian Research Agency (P1–0207), by the FP7 WeNMR (No. 261572) and H2020 West-Life (No. 675858) grants, and by a grant for the Research Cooperation of Doctoral Students Abroad in Year 2014 (Official Gazette of the Republic of Slovenia, No. 89/14).
Weitere Informationen

Publikationsverlauf

17. Mai 2018

24. Juli 2018

Publikationsdatum:
20. September 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Components of the intrinsic blood coagulation pathway, among them factor VIIIa (FVIIIa), have been recognized as suitable therapeutic targets to treat venous thromboembolism, pathological process behind two very serious cardiovascular diseases, deep vein thrombosis and pulmonary embolism. Here, we describe a unique glycoprotein from the nose-horned viper (Vipera ammodytes ammodytes [Vaa]) venom, Vaa serine proteinase homolog 1 (VaaSPH-1), structurally a serine protease but without an enzymatic activity and expressing potent anticoagulant action in human blood. We demonstrated that one of its targets in the blood coagulation system is FVIIIa of the intrinsic tenase complex, where it antagonizes the binding of FIXa. Anticoagulants with such characteristics are intensively sought, as they would be much safer for medical application as the contemporary drugs, which frequently induce excessive bleeding and other complications. VaaSPH-1 is unlikely to be orally available for chronic usage as it has molecular mass of 35 kDa. However, it represents a very promising template to design low molecular mass FVIIIa-directed anticoagulant substances, based on structural features of the interaction surface between VaaSPH-1 and FVIIIa. To this end, we constructed a three-dimensional model of VaaSPH-1 bound to FVIIIa. The model exposes the 157–loop and the preceding α-helix as the most appropriate structural elements of VaaSPH-1 to be considered as a guideline to synthesize small FVIIIa-binding molecules, potential new generation of anticoagulants.

Keywords

snake venoms - haemostasis - coagulation inhibitors - factor VIII inhibitors - venous thrombosis

Supplementary Material

 

  • References

  • 1 Langford Nj, Stansby G, Avital L. The management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE Guideline CG144. Acute Med 2012; 11 (03) 138-142
    PubMedGoogle Scholar
  • 2 Smith ML. The expanding role of direct oral anticoagulants in the management of thromboembolic disease. Drug Top 2016; 4: 54-61
    PubMedGoogle Scholar
  • 3 Kim JH, Lim K-M, Gwak HS. New anticoagulants for the prevention and treatment of venous thromboembolism. Biomol Ther (Seoul) 2017; 25 (05) 461-470
    CrossrefPubMedGoogle Scholar
  • 4 Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 3-14
    CrossrefPubMedGoogle Scholar
  • 5 Wolberg AS, Rosendaal FR, Weitz JI. , et al. Venous thrombosis. Nat Rev Dis Primers 2015; 1: 15006
    CrossrefPubMedGoogle Scholar
  • 6 Kesieme E, Kesieme C, Jebbin N, Irekpita E, Dongo A. Deep vein thrombosis: a clinical review. J Blood Med 2011; 2: 59-69
    PubMedGoogle Scholar
  • 7 Cheng Y, Liu Z, Yao F. , et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. In: Lowe G, ed. PLoS Med 2013; 10 (09) e1001515 . Doi:10.1371/journal.pmed.1001515
    PubMed
  • 8 Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology (Am Soc Hematol Educ Program) 2005; 1: 1-12
    PubMedGoogle Scholar
  • 9 Wakefield TW, Caprini J, Comerota AJ. Thromboembolic diseases. Curr Probl Surg 2008; 45 (12) 844-899
    CrossrefPubMedGoogle Scholar
  • 10 Peterson JA, Maroney SA, Mast AE. Targeting TFPI for hemophilia treatment. Thromb Res 2016; 141 (Suppl. 02) S28-S30
    CrossrefPubMedGoogle Scholar
  • 11 Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P&T 2010; 35 (02) 95-105
    PubMedGoogle Scholar
  • 12 Junqueira DR, Zorzela LM, Perini E. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 2017; 4: CD007557
    Google Scholar
  • 13 Levy JH, Spyropoulos AC, Samama CM, Douketis J. Direct oral anticoagulants: new drugs and new concepts. JACC Cardiovasc Interv 2014; 7 (12) 1333-1351
    CrossrefPubMedGoogle Scholar
  • 14 McRae SJ, Ginsberg JS. New anticoagulants for the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag 2005; 1 (01) 41-53
    CrossrefPubMedGoogle Scholar
  • 15 Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 2015; 11: 967-977
    CrossrefPubMedGoogle Scholar
  • 16 Tummala R, Kavtaradze A, Gupta A, Ghosh RK. Specific antidotes against direct oral anticoagulants: a comprehensive review of clinical trials data. Int J Cardiol 2016; 214: 292-298
    CrossrefPubMedGoogle Scholar
  • 17 Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16 (1-2): 17-20
    CrossrefPubMedGoogle Scholar
  • 18 Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol Dis 2006; 36 (02) 108-117
    CrossrefPubMedGoogle Scholar
  • 19 Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451 (7181): 914-918
    PubMedGoogle Scholar
  • 20 Mackman N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol 2005; 25 (11) 2273-2281
    CrossrefPubMedGoogle Scholar
  • 21 Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27 (12) 2507-2513
    PubMedGoogle Scholar
  • 22 Machlus KR, Lin FC, Wolberg AS. Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood 2011; 118 (14) 3960-3968
    CrossrefPubMedGoogle Scholar
  • 23 Nicolaes GA, Kulharia M, Voorberg J. , et al. Rational design of small molecules targeting the C2 domain of coagulation factor VIII. Blood 2014; 123 (01) 113-120
    CrossrefPubMedGoogle Scholar
  • 24 Schwarb H, Tsakiris DA. New direct oral anticoagulants (DOAC) and their use today. Dent J (Basel) 2016; 4 (01) 5
    CrossrefPubMedGoogle Scholar
  • 25 Venkateswarlu D. Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: a computational protein-protein docking and molecular dynamics refinement study. Biochem Biophys Res Commun 2014; 452 (03) 408-414
    CrossrefPubMedGoogle Scholar
  • 26 Chow FS, Benincosa LJ, Sheth SB. , et al. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 2002; 71 (04) 235-245
    CrossrefPubMedGoogle Scholar
  • 27 Toomey JR, Valocik RE, Koster PF. , et al. Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. Stroke 2002; 33 (02) 578-585
    CrossrefPubMedGoogle Scholar
  • 28 Howard EL, Becker KCD, Rusconi CP, Becker RC. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 2007; 27 (04) 722-727
    CrossrefPubMedGoogle Scholar
  • 29 Vadivel K, Schmidt AE, Marder VJ, Krishnaswamy S, Bajaj S. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2012
    Google Scholar
  • 30 Eriksson BI, Dahl OE, Lassen MR. , et al; Fixit Study Group. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost 2008; 6 (03) 457-463
    CrossrefPubMedGoogle Scholar
  • 31 Lincoff AM, Mehran R, Povsic TJ. , et al; REGULATE-PCI Investigators. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet 2016; 387 (10016): 349-356
    CrossrefPubMedGoogle Scholar
  • 32 De Caterina R, Husted S, Wallentin L. , et al; European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (Section I). Thromb Haemost 2013; 109 (04) 569-579
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 33 Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis 2011; 5 (01) 33-59
    CrossrefPubMedGoogle Scholar
  • 34 Anastasopoulos C, Sarigiannis Y, Stavropoulos G. A novel approach in potential anticoagulants from peptides epitope 558-565 of A2 subunit of factor VIII. Amino Acids 2013; 44 (04) 1159-1165
    CrossrefPubMedGoogle Scholar
  • 35 Slagboom J, Kool J, Harrison RA, Casewell NR. Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise. Br J Haematol 2017; 177 (06) 947-959
    CrossrefPubMedGoogle Scholar
  • 36 McCleary RJR, Kini RM. Non-enzymatic proteins from snake venoms: a gold mine of pharmacological tools and drug leads. Toxicon 2013; 62: 56-74
    CrossrefPubMedGoogle Scholar
  • 37 Mukherjee AK, Mackessy SP. Pharmacological properties and pathophysiological significance of a Kunitz-type protease inhibitor (Rusvikunin-II) and its protein complex (Rusvikunin complex) purified from Daboia russelii russelii venom. Toxicon 2014; 89: 55-66
    CrossrefPubMedGoogle Scholar
  • 38 Sajevic T, Leonardi A, Križaj I. An overview of hemostatically active components of Vipera ammodytes ammodytes venom. Toxin Rev 2014; 33 (1–2): 33-36
    CrossrefPubMedGoogle Scholar
  • 39 Latinović Z, Leonardi A, Šribar J. , et al. Venomics of Vipera berus berus to explain differences in pathology elicited by Vipera ammodytes ammodytes envenomation: therapeutic implications. J Proteomics 2016; 146: 34-47
    CrossrefPubMedGoogle Scholar
  • 40 Leonardi A, Sajevic T, Latinović Z. , et al. Structural and biochemical characterisation of VaF1, a P-IIIa fibrinogenolytic metalloproteinase from Vipera ammodytes ammodytes venom. Biochimie 2015; 109: 78-87
    CrossrefPubMedGoogle Scholar
  • 41 Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004; 32 (05) 1792-1797
    CrossrefPubMedGoogle Scholar
  • 42 Sajevic T, Leonardi A, Kovačič L. , et al. VaH3, one of the principal hemorrhagins in Vipera ammodytes ammodytes venom, is a homodimeric P-IIIc metalloproteinase. Biochimie 2013; 95 (06) 1158-1170
    CrossrefPubMedGoogle Scholar
  • 43 Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011; 127 (Suppl. 03) S21-S25
    CrossrefPubMedGoogle Scholar
  • 44 Lancé MD. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J 2015; 13: 1
    CrossrefPubMedGoogle Scholar
  • 45 Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 2004; 32 (Web Server issue): W526-31
    PubMedGoogle Scholar
  • 46 Zeng F, Shen B, Zhu Z. , et al. Crystal structure and activating effect on RyRs of AhV_TL-I, a glycosylated thrombin-like enzyme from Agkistrodon halys snake venom. Arch Toxicol 2013; 87 (03) 535-545
    CrossrefPubMedGoogle Scholar
  • 47 Šali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234 (03) 779-815
    CrossrefPubMedGoogle Scholar
  • 48 Fiser A, Do RK, Šali A. Modeling of loops in protein structures. Protein Sci 2000; 9 (09) 1753-1773
    CrossrefPubMedGoogle Scholar
  • 49 Johnson DJD, Langdown J, Huntington JA. Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex. Proc Natl Acad Sci U S A 2010; 107 (02) 645-650
    CrossrefPubMedGoogle Scholar
  • 50 Johnson DJD, Li W, Adams TE, Huntington JA. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J 2006; 25 (09) 2029-2037
    CrossrefPubMedGoogle Scholar
  • 51 Berling I, Isbister GK. Hematologic effects and complications of snake envenoming. Transfus Med Rev 2015; 29 (02) 82-89
    CrossrefPubMedGoogle Scholar
  • 52 Waheed H, Moin SF, Choudhary MI. Snake venom: from deadly toxins to life-saving therapeutics. Curr Med Chem 2017; 24 (17) 1874-1891
    PubMedGoogle Scholar
  • 53 Barrett AJ, Rawlings ND. Families and clans of serine peptidases. Arch Biochem Biophys 1995; 318 (02) 247-250
    CrossrefPubMedGoogle Scholar
  • 54 Vaiyapuri S, Thiyagarajan N, Hutchinson EG, Gibbins JM. Sequence and phylogenetic analysis of viper venom serine proteases. Bioinformation 2012; 8 (16) 763-772
    CrossrefPubMedGoogle Scholar
  • 55 Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100 (01) 148-152
    CrossrefPubMedGoogle Scholar
  • 56 Young G, Sørensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013; 121 (11) 1944-1950
    CrossrefPubMedGoogle Scholar
  • 57 Serrano SMT, Maroun RC. Snake venom serine proteinases: sequence homology vs. substrate specificity, a paradox to be solved. Toxicon 2005; 45 (08) 1115-1132
    CrossrefPubMedGoogle Scholar
  • 58 Spencer FA, Becker RC. The prothrombinase complex: assembly and function. J Thromb Thrombolysis 1997; 4 (3/4): 357-364
    CrossrefPubMedGoogle Scholar
  • 59 Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003; 42 (05) 423-438
    CrossrefPubMedGoogle Scholar
  • 60 Zwaal RF. Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta 1978; 515 (02) 163-205
    CrossrefPubMedGoogle Scholar
  • 61 Bevers EM, Rosing J, Zwaal RF. Development of procoagulant binding sites on the platelet surface. Adv Exp Med Biol 1985; 192: 359-371
    CrossrefPubMedGoogle Scholar
  • 62 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22 (09) 1381-1389
    CrossrefPubMedGoogle Scholar
  • 63 Perot E, Enjolras N, Le Quellec S. , et al. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity. Thromb Res 2015; 135 (05) 1017-1024
    CrossrefPubMedGoogle Scholar
  • 64 Jagannathan I, Ichikawa HT, Kruger T, Fay PJ. Identification of residues in the 558-loop of factor VIIIa A2 subunit that interact with factor IXa. J Biol Chem 2009; 284 (47) 32248-32255
    CrossrefPubMedGoogle Scholar
  • 65 Anastasopoulos C, Sarigiannis Y, Stavropoulos G. Cyclic peptide analogs of 558-565 epitope of A2 subunit of Factor VIII prolong aPTT. Toward a novel synthesis of anticoagulants. Amino Acids 2014; 46 (04) 1087-1096
    CrossrefPubMedGoogle Scholar
  • 66 Verhamme P, Pakola S, Jensen TJ. , et al. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther 2010; 32 (06) 1205-1220
    CrossrefPubMedGoogle Scholar
  • 67 Arruda VR, Doshi BS, Samelson-Jones BJ. Novel approaches to hemophilia therapy: successes and challenges. Blood 2017; 130 (21) 2251-2256
    CrossrefPubMedGoogle Scholar